RT.. Umbilical Cord Blood Stem Cells Utilized by USF Researchers to Treat Heart Attack... [DVBNVMN]
Umbilical Cord Blood Stem Cells Utilized by USF Researchers to Treat Heart Attack in Animals
OLDSMAR, Fla., Jan. 11 /PRNewswire-FirstCall/ -- Researchers from the University of South Florida ("USF") and James A. Haley Veterans Hospital have reported in the journal "Cell Transplantation" that stem cells from umbilical cord blood effectively treated heart attacks in an animal study. Injected into rats' hearts after heart attack, human umbilical cord blood cells were shown to greatly reduce the size of heart damage and restored pumping function to near normal.
The USF study was supported by the American Heart Association, the Veterans Administration, a Florida biomedical research grant and Saneron CCEL Therapeutics, Inc., an affiliate of CRYO-CELL International, Inc. (OTC Bulletin Board: CCEL). Some study authors are affiliated with Saneron and are co-inventors on related patent applications by USF. Paul Sanberg, Ph.D., D.Sc., co-author of the study, commented, "Cord blood stem cells may be more amenable to cardiac repair than those taken from other sources like bone marrow or skeletal muscle. In addition, cord blood is readily accessible, easy to use, and non-controversial when compared to embryonic stem cells."
"Results from this recent study demonstrate that human umbilical cord blood cells have regenerative cardiac effects in animal studies," stated Mercedes Walton, CRYO-CELL's Chairman and interim CEO. "In view of the widespread prevalence of heart disease, cell therapies may have future human application, which could actually strengthen cardiac muscle, thereby restoring cardiac function. Although this research is preliminary and the reported trials are pre-clinical, early indications are very promising and its potential represents a compelling reason for parents to consider banking their newborn's cord blood." CRYO-CELL International, Inc. owns approximately 43% equity in Saneron CCEL.
About CRYO-CELL International, Inc.
Based in Oldsmar, Florida, CRYO-CELL is the world's largest U-Cord(R) stem cell banking firm, offering high-quality cord blood preservation exclusively for the benefit of newborn babies and possibly other members of their family. CRYO-CELL is accredited by the American Association of Blood Banks (AABB). CRYO-CELL is a publicly traded company. OTC Bulletin Board Symbol ... CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit cryo-cell.com .
About Saneron CCEL Therapeutics, Inc.
Saneron CCEL Therapeutics, Inc. is a biotechnology R&D startup company focused on cell therapy for the early intervention and treatment of several devastating or deadly diseases, which currently lack adequate treatment options. Saneron CCEL, located at the USF Center for Entrepreneurship in Tampa, FL, was created by the merger of Saneron Therapeutics, Inc. and CCEL Bio-Therapies, Inc., formerly a wholly owned subsidiary of CRYO-CELL International, Inc. Saneron CCEL is committed to providing readily available, non-controversial stem cells for cellular therapies and has exclusively licensed patented technology relating to our platform technology of U-CORD-CELL(TM) -- umbilical cord blood, and SERT-CELL(TM) -- Sertoli cells.
Forward-Looking Statement
Statements wherein the terms "believes," "intends," "projects" or "expects" as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include any adverse effect or limitations caused by any governmental regulations, proceedings or actions, foreign and domestic; any continued or increased losses, or any inability to obtain acceptable financing, where desirable in the future, in connection with our operating or growth plans; any increased competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees; the effect of any future reduced cash position and future inability to access borrowings; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the move into our new facility or the operation of the facility; any adverse developments impacting our continued relationship with and success of our licensees, foreign affiliates or investments in, or relationships with, foreign companies; any inability to achieve increases in revenue or earnings from umbilical cord blood stem cell storage; any future inability to substantially achieve the objectives expected from the successful implementation of our strategy; any decline in public market interest in the Company's business sector; any added requirements imposed on us by new laws or SEC regulations and costs thereof; any technological breakthrough or medical breakthrough that would render the Company's business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the potential impact of negative market influences on the Company's portfolio of cash, cash equivalents and marketable securities; the costs associated with defending or prosecuting litigation matters and any material adverse result from such matters; decreases in asset valuations; any continued negative effect from adverse publicity in the past year regarding the Company's business operations; any new technology rendering the Company's patented equipment or business obsolete; any performance failures related to the Company's equipment or operations; any negative consequences resulting from deriving, shipping and storing specimens at a second location; any negative effect from the filed class action shareholder lawsuits; and other risks and uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed by the Company. SOURCE CRYO-CELL International, Inc. 11Jan05 14:03 GMT
Symbols: de;ZCY de;ZCYF us;CCEL
Source PRN PR Newswire
Categories: MST/I/BTC MST/I/DRG MST/I/EDU MST/I/HCS MST/I/HEA MST/L/EN MST/R/US/FL TGT/PRX |
